Clinical efficacy and safety of interferon-β–containing regimens in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

References

• WHO. [ cited 2021 Jul 20]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404–412.
   PubMedGoogle Scholar
• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
   PubMed Web of Science ®Google Scholar
• Lai CC, Chao CM, Hsueh PR., et al. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021;(5). DOI: https://doi.org/10.1016/j.jmii.2021.05.011.
   Google Scholar
• WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021 Jul 6:e2111330. DOI:https://doi.org/10.1001/jama.2021.11330.
   Google Scholar
• WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341.
   PubMed Web of Science ®Google Scholar
• Sallard E, Lescure FX, Yazdanpanah Y, et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791.
   PubMed Web of Science ®Google Scholar
• Spiegel M, Pichlmair A, Mühlberger E, et al. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. J Clin Virol. 2004;30(3):211–213.
   PubMed Web of Science ®Google Scholar
• Sainz B Jr., Mossel EC, Peters CJ, et al. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004;329(1):11–17.
   PubMed Web of Science ®Google Scholar
• Hensley LE, Fritz LE, Jahrling PB, et al. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis. 2004;10(2):317–319.
   PubMed Web of Science ®Google Scholar
• Ader F, Peiffer-Smadja N, Poissy J, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021. DOI:https://doi.org/10.1016/j.cmi.2021.05.020.
   Google Scholar
• Alavi Darazam I, Hatami F, Mahdi Rabiei M, et al. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: the COVIFERON II randomized controlled trial. Int Immunopharmacol. 2021;99:107916.
   PubMed Web of Science ®Google Scholar
• Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep. 2021;11(1):8059. Sci. Rep.:8059.
   PubMed Web of Science ®Google Scholar
• Davoudi-Monfared E, Rahmani H, and Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9) :e01061–20.
   PubMed Web of Science ®Google Scholar
• Khamis F, Al Naabi H, Al Lawati A, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;102:538–543.
   PubMed Web of Science ®Google Scholar
• Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196–206.
   PubMed Web of Science ®Google Scholar
• Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol. 2020;88:106903.
   PubMed Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103–112.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for covid-19 – interim WHO solidarity trial results. N Engl J Med. 2021;384:497–511.
   PubMed Web of Science ®Google Scholar
• Tortajada C, Añón S, Ortiz MM, et al. Interferon β-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease. J Med Virol. 2021;93(7):4102–4107.
   PubMed Web of Science ®Google Scholar
• Nakhlband A, Fakhari A, Azizi H., et al. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(5):829–838.
   PubMed Web of Science ®Google Scholar